{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:25:26Z","timestamp":1785558326614,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00392-019-01448-4","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T11:06:48Z","timestamp":1552302408000},"page":"1128-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cardioprotective effect of renin\u2013angiotensin inhibitors and \u03b2-blockers in trastuzumab-related cardiotoxicity"],"prefix":"10.1007","volume":"108","author":[{"given":"Kisho","family":"Ohtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"issue":"4785","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"36","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24(36):5658\u20135663. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.07.0250","journal-title":"J Clin Oncol"},{"issue":"9555","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, team Hs (2007) 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29\u201336. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)60028-2","journal-title":"Lancet"},{"issue":"11","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792. \n                    https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"issue":"16","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"issue":"19","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O\u2019Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265\u20134274. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.04.173","journal-title":"J Clin Oncol"},{"issue":"16","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"issue":"4","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2042098614529603","volume":"5","author":"AA Onitilo","year":"2014","unstructured":"Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5(4):154\u2013166. \n                    https:\/\/doi.org\/10.1177\/2042098614529603","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","volume":"106","author":"GW Keulenaer De","year":"2010","unstructured":"De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106(1):35\u201346. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.205906","journal-title":"Circ Res"},{"issue":"6","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","volume":"15","author":"N Mohan","year":"2016","unstructured":"Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ (2016) Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther 15(6):1321\u20131331. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0741","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","volume":"284","author":"LI Gordon","year":"2009","unstructured":"Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284(4):2080\u20132087. \n                    https:\/\/doi.org\/10.1074\/jbc.M804570200","journal-title":"J Biol Chem"},{"issue":"13","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23(13):2900\u20132902. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.05.827","journal-title":"J Clin Oncol"},{"key":"1448_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D\u2019Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"1448_CR14","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nole F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910\u20133916. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.3615","journal-title":"J Clin Oncol"},{"issue":"23","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3525\u20133533. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.11.0106","journal-title":"J Clin Oncol"},{"issue":"21","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol 28(21):3422\u20133428. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.0463","journal-title":"J Clin Oncol"},{"issue":"25","key":"1448_CR17","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107\u20134115. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.04.9551","journal-title":"J Clin Oncol"},{"issue":"13","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900\u20132909. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030","journal-title":"Eur J Cancer"},{"key":"1448_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1386-0","author":"K Ohtani","year":"2018","unstructured":"Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K, Tsutsui H (2018) Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol. \n                    https:\/\/doi.org\/10.1007\/s00392-018-1386-0","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911\u2013939. \n                    https:\/\/doi.org\/10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"issue":"14","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research G (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"issue":"20","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32(20):2159\u20132165. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.9288","journal-title":"J Clin Oncol"},{"issue":"13","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900\u2013905. \n                    https:\/\/doi.org\/10.1056\/NEJM199809243391307","journal-title":"N Engl J Med"},{"issue":"25","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808\u20133815. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.10.4976","journal-title":"J Clin Oncol"},{"issue":"31","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811\u20137819. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.02.4091","journal-title":"J Clin Oncol"},{"issue":"15","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","volume":"50","author":"LW Jones","year":"2007","unstructured":"Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50(15):1435\u20131441. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2007.06.037","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1448_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell K, Arab S, Haring B, Kuhn B (2009) Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2):257\u2013270. \n                    https:\/\/doi.org\/10.1016\/j.cell.2009.04.060","journal-title":"Cell"},{"issue":"5","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596\u2013603. \n                    https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.973321","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"1448_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","volume":"99","author":"A Farolfi","year":"2013","unstructured":"Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99(9):634\u2013639. \n                    https:\/\/doi.org\/10.1136\/heartjnl-2012-303151","journal-title":"Heart"},{"issue":"19","key":"1448_CR30","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1200\/JCO.2015.65.1505","volume":"34","author":"P Thavendiranathan","year":"2016","unstructured":"Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, Lee DS (2016) Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol 34(19):2239\u20132246. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.65.1505","journal-title":"J Clin Oncol"},{"issue":"24","key":"1448_CR31","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504\u20132512. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"1448_CR32","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792\u20133799. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.40.0010","journal-title":"J Clin Oncol"},{"issue":"3","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-016-3823-y","volume":"157","author":"IY Gong","year":"2016","unstructured":"Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK (2016) Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Res Treat 157(3):535\u2013544. \n                    https:\/\/doi.org\/10.1007\/s10549-016-3823-y","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1448_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A, Investigators Pt (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741\u2013748. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70225-0","journal-title":"Lancet Oncol"},{"issue":"7","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","volume":"26","author":"D Mavroudis","year":"2015","unstructured":"Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V, Breast Cancer Investigators of Hellenic Oncology Research Group AG (2015) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 26(7):1333\u20131340. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv213","journal-title":"Ann Oncol"},{"issue":"15","key":"1448_CR36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","volume":"135","author":"HK Narayan","year":"2017","unstructured":"Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B (2017) Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135(15):1397\u20131412. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023463","journal-title":"Circulation"},{"issue":"9","key":"1448_CR37","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1096\/fj.09-131383","volume":"23","author":"G Riccio","year":"2009","unstructured":"Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D\u2019Alessio G, De Lorenzo C (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23(9):3171\u20133178. \n                    https:\/\/doi.org\/10.1096\/fj.09-131383","journal-title":"FASEB J"},{"issue":"1","key":"1448_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","volume":"2","author":"C Dang","year":"2016","unstructured":"Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM (2016) Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2(1):29\u201336. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.3709","journal-title":"JAMA Oncol"},{"key":"1448_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv301","author":"HA Goldhar","year":"2016","unstructured":"Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK (2016) The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv301","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","volume":"6","author":"S Seicean","year":"2013","unstructured":"Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH (2013) Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 6(3):420\u2013426. \n                    https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000055","journal-title":"Circ Heart Fail"},{"issue":"8","key":"1448_CR41","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35(8):870\u2013877. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"issue":"21","key":"1448_CR42","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"issue":"8","key":"1448_CR43","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH (2016) Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2(8):1030\u20131037. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.1726","journal-title":"JAMA Oncol"},{"issue":"31","key":"1448_CR44","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31):7820\u20137826. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.13.300","journal-title":"J Clin Oncol"},{"issue":"4","key":"1448_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00392-018-1202-x","volume":"107","author":"LM Tilemann","year":"2018","unstructured":"Tilemann LM, Heckmann MB, Katus HA, Lehmann LH, Muller OJ (2018) Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107(4):271\u2013280. \n                    https:\/\/doi.org\/10.1007\/s00392-018-1202-x","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01448-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:12:10Z","timestamp":1583799130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01448-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01448-4","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Tsutsui has received the research grant from Actelion, Daichii-Sankyo, and Astellas, and lecture fees from Astellas, Otsuka, Takeda, Daichii-Sankyo, Mitsubishi Tanabe, Boehringer Ingelheim, Novartis, Bayer, and Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}